- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05956834
A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes
The primary objective of this study is to enroll an observational cohort of approximately 60 patients with PSP over the course of 24 months using a multicenter study design and to follow each of them for 12 months.
The secondary objective of this study is to develop a robust solution for multi-modal remote monitoring of motor symptoms and function in PSP that can be applied to other Frontotemporal lobar degeneration (FTLD) syndromes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Mansi Sharma, BS
- Phone Number: 6176432400
- Email: msharma13@mgh.harvard.edu
Study Contact Backup
- Name: Anne-Marie A Wills, MD MPH
- Phone Number: 16177265532
- Email: awills@mgh.harvard.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21093
- Recruiting
- Johns Hopkins School of Medicine
-
Principal Investigator:
- Alex Pantelyat, MD
-
Contact:
- AJ Hall
- Phone Number: 410-616-2813
- Email: ahall52@jhmi.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Principal Investigator:
- Anne-Marie A Wills, MD MPH
-
Contact:
- Mansi Sharma
- Phone Number: 617-643-2400
- Email: msharma13@mgh.harvard.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Clinical diagnosis of possible or probable PSP as defined by the 2017 MDS criteria
- Fluent in reading and speaking English and capable of providing informed consent based on the principal investigator's judgement
- Able to walk 10 feet unassisted at the time of initial enrollment
- Must have a caregiver or study partner who is willing and able to assist with all study-related procedures
Exclusion Criteria:
- Any neurological, medical, or psychiatric condition that would preclude participation in study activities based on the investigator's judgment.
- A history of frequent falls defined as more than 5 falls per month, or who require a walker to ambulate safely at baseline will not be eligible to participate in the study.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility
Time Frame: 12 months
|
Feasibility will be defined by the number of participants who complete the 12 month study and who wear their PAMSys pendant sensors at least 16 hours/day for at least 75% of the designated sensor days (7 days per month).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSPRS
Time Frame: 12 months
|
The Progressive Supranuclear Palsy Rating Scale will be administered in-person every 3 months.
The PSPRS is a 28 item scale with a total score of 0-100 where lower scores are less affected.
|
12 months
|
Cortical Basal ganglia Functional Scale (CBFS)
Time Frame: 12 months
|
The Cortical Basal ganglia Functional Scale (CBFS) will be performed every 3 months.
The CBFS is a 31 item scale, with a total of 124 possible points, where a lower score is less affected.
|
12 months
|
PSP Quality of Life scale (PSP QoL)
Time Frame: 12 months
|
The PSP Quality of Life scale will be performed every 3 months.
The PSP-QoL is a 45 item scale, with a possible scale of 0-100 with lower scores less affected.
|
12 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Eye Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Dementia
- Tauopathies
- Cranial Nerve Diseases
- Ocular Motility Disorders
- Language Disorders
- Communication Disorders
- Paralysis
- Speech Disorders
- Ophthalmoplegia
- Aphasia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
- Supranuclear Palsy, Progressive
- Frontotemporal Lobar Degeneration
- Corticobasal Degeneration
Other Study ID Numbers
- IRB00341607
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Corticobasal Degeneration
-
AbbVieNo longer availablePrimary Tauopathy Corticobasal Degeneration Syndrome (CBD)
-
Technical University of MunichRecruitingCorticobasal Syndrome (CBS)Germany
-
Johns Hopkins UniversityRecruitingUpper Extremity Dysfunction | Corticobasal SyndromeUnited States
-
Johns Hopkins UniversityRecruitingCorticobasal Degeneration | Corticobasal Syndrome | Pain, NeuropathicUnited States
-
University of California, San FranciscoTau Consortium; CBD SolutionsCompletedProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Corticobasal Syndrome (CBS) | Primary Four Repeat Tauopathies (4RT)United States
-
Ludwig-Maximilians - University of MunichActive, not recruitingAlzheimer Disease | Corticobasal Syndrome
-
University of California, San FranciscoNational Institutes of Health (NIH); National Institute on Aging (NIA)Active, not recruitingProgressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Corticobasal Syndrome (CBS) | Cortical-basal Ganglionic Degeneration (CBGD) | Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)United States, Canada
-
Amoneta Diagnostics SASAssistance Publique - Hôpitaux de Paris; University Hospital, Geneva; University... and other collaboratorsUnknownFrontotemporal Lobar Degeneration | Progressive Supranuclear Palsy (PSP) | Dementia With Lewy Bodies (DLB) | Corticobasal Degeneration (CBD) | Alzheimer Disease (AD) | Parkinson Disease Dementia (PDD)Belgium, France, Italy, Switzerland, Turkey
-
University of California, San FranciscoTerminatedNonfluent Aphasia, Progressive | Primary Tauopathies | Corticobasal Degeneration Syndrome | Frontotemporal Lobar Degeneration With Tau Inclusions | MAPT Mutation Carriers, Symptomatic | Traumatic Encephalopathy SyndromeUnited States
-
University of PennsylvaniaUnited States Department of Defense; National Institutes of Health (NIH); National... and other collaboratorsRecruitingFrontotemporal Degeneration(FTD) | Primary Progressive Aphasia(PPA) | Familial Frontotemporal Lobar Degeneration (fFTLD) | Amyotrophic Lateral Sclerosis(ALS) | Lewy Body Disease(LBD) | Progressive Supranuclear Palsy(PSP) | Corticobasal Syndrome(CBS) | Posterior Cortical Atrophy(PCA) | Alzheimer's Disease(AD)United States
Clinical Trials on PAMSys
-
University of Kansas Medical CenterBioSensicsRecruitingInclusion Body MyositisUnited States
-
Milton S. Hershey Medical CenterBioSensicsRecruiting